A case of direct-antiglobulin-test (DAT)-negative auto-immune haemolytic anaemia (AIHA) and immune thrombocytopenia (ITP) associated with Hodgkin’s disease (HD) is reported. A 52-year-old male was admitted with anaemia, thrombocytopenia, and lymphadenopathy. The patient was DAT negative, although he exhibited the clinical features of warm-type AIHA and elevated levels of red-blood-cell-associated IgG (RBC-IgG). The serum level of platelet-associated IgG (PA-IgG) was markedly increased. A biopsy specimen of the inguinal lymph nodes showed HD of mixed cellularity. Marked improvement of subjective symptoms, normalization of haematological values and a decrease in the level of both RBC- and PA-IgG were observed after the start of combination chemotherapy for HD. Although the association of HD, ITP, and/or AIHA has been infrequently reported, the measurement of RBC-IgG is recommended in cases of HD with anaemia even though DAT is negative, since HD is known to be associated with various protean immunological abnormalities.

Keywords:
Coombs’ test, DAT negative, Evans syndrome, Immune thrombocytopenia, Hodgkin’s disease, Platelet-associated IgG, RBC-associated IgG
1.
Gilland BC: Coombs-negative immune hemolytic anemia. Semin Hematol 1976;13:267–275.
2.
Kajii E, Omine T, Miura S, Ikemoto N: A new approach for diagnosis of autoimmune hemolytic anemia. Rinsho Ketsueki 1993;35:336–340.
3.
Kondo H, Kajii E, Oyamada T, Kasahara Y: Direct antiglobulin negative autoimmune hemolytic anemia associated with autoimmune hepatitis. Int J Hematol 1998;68:439–443.
4.
Eisner E, Ley AB, Mayer K: Coombs’ positive hemolytic anemia in Hodgkin disease. Ann Intern Med 1967;66:258–273.
5.
Levine AM, Thornton P, Forman SJ, Van Hale P, Holdorf D, Rouault CL, Powars D, Feinstein DI, Lukes RJ: Positive Coombs test in Hodgkin’s disease: Significance and implications. Blood 1980;55:607–611.
6.
Majumadar G: Unremitting severe autoimmune haemolytic anaemia as a presenting feature of Hodgkin’s disease. Leuk Lymphma 1995;20:169–172.
7.
Xiros N, Binder T, Anger B, Bohlke J, Heimpel H: Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin disease. Eur J Haematol 1988;40:437–441.
8.
Martinelli G, Zinzani PL, Magagnoli M, Vianelli N, Tura S: Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin’s disease in complete hematological remission. Haematologica 1998;83:669–670.
9.
Stah SJ, Warrier RP, Ode DL, Lele HE, Yu LC: Immune thrombocytopenia and hemolytic anemia associated with Hodgkin disease. J Pediatr Hematol Oncol 1996;18:227–229.
10.
Ertem M, Uysal Z, Yavuz G, Gozdasoglu S: Immune thrombocytopenia and hemolytic anemia as a presenting manifestation of Hodgkin disease. Pediatr Hematol Oncol 2000;17:181–185.
11.
Keung YK, Cobos E, Bolanos-Maede, Issarachai S, Brideau A, Morgan D: Evans syndrome after autologous bone marrow transplantation for recurrent Hodgkin’s disease. Bone Marrow Transplant 1997;20:1099–1100.
12.
Jeje MO, Blajchman MA, Steeves K, Horsewood P, Kelton JG: Quantitation of red cell associated IgG using an immunoradiometric assay. Transfusion 1984;24:473–476.
13.
Kondo H, Sakai S, Sai K, Kubo T, Hoshino K, Nakada H, Nanabe K, Hachisu H, Takaso T: Specificity and clinical significance of platelet-associated IgG with various disease. Chiba Med 1993;69:43–52.
14.
George JN: Platelet immunoglobulin G. Its significance for the evaluation of thrombocytopenia and for understanding the origin of α-granule proteins. Blood 1990;859–870.
15.
Costello RT, Xerri L, Bouabdallah R, Gastaut J-A, Sainty D: Leukopenia, thrombocytopenia, and acute autoimmune hemolytic anemia associated with an unusual (type 2/4) Hodgkin’s disease. Am J Hematol 1998;333–334.
16.
Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI: The impact of Hodgkin’s disease on the immune system. Semin Oncol 1990;17:673–682.
17.
Haluska FG, Brufsky AM, Canellos GP: The cellular biology of the Reed-Sternberg cell. Blood 1994;84:1005–1019.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.